Movatterモバイル変換


[0]ホーム

URL:


SG10201913147WA - Agonist antibodies that bind human cd137 and uses thereof - Google Patents

Agonist antibodies that bind human cd137 and uses thereof

Info

Publication number
SG10201913147WA
SG10201913147WASG10201913147WASG10201913147WASG10201913147WASG 10201913147W ASG10201913147W ASG 10201913147WASG 10201913147W ASG10201913147W ASG 10201913147WASG 10201913147W ASG10201913147W ASG 10201913147WASG 10201913147W ASG10201913147W ASG 10201913147WA
Authority
SG
Singapore
Prior art keywords
bind human
agonist antibodies
agonist
antibodies
bind
Prior art date
Application number
SG10201913147WA
Inventor
Piotr Bobrowicz
Paul Widboom
Michael Schmidt
Jason Lajoie
Robert Tighe
Cheuk Leung
Ugur Eskiocak
Original Assignee
Compass Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Compass Therapeutics LlcfiledCriticalCompass Therapeutics Llc
Publication of SG10201913147WApublicationCriticalpatent/SG10201913147WA/en

Links

Classifications

Landscapes

SG10201913147WA2017-07-112018-07-11Agonist antibodies that bind human cd137 and uses thereofSG10201913147WA (en)

Applications Claiming Priority (5)

Application NumberPriority DateFiling DateTitle
US201762531259P2017-07-112017-07-11
US201762531190P2017-07-112017-07-11
US201762568231P2017-10-042017-10-04
US201762577257P2017-10-262017-10-26
US201762577259P2017-10-262017-10-26

Publications (1)

Publication NumberPublication Date
SG10201913147WAtrue SG10201913147WA (en)2020-02-27

Family

ID=63036491

Family Applications (3)

Application NumberTitlePriority DateFiling Date
SG11201913137VASG11201913137VA (en)2017-07-112018-07-11Agonist antibodies that bind human cd137 and uses thereof
SG10201913144TASG10201913144TA (en)2017-07-112018-07-11Agonist antibodies that bind human cd137 and uses thereof
SG10201913147WASG10201913147WA (en)2017-07-112018-07-11Agonist antibodies that bind human cd137 and uses thereof

Family Applications Before (2)

Application NumberTitlePriority DateFiling Date
SG11201913137VASG11201913137VA (en)2017-07-112018-07-11Agonist antibodies that bind human cd137 and uses thereof
SG10201913144TASG10201913144TA (en)2017-07-112018-07-11Agonist antibodies that bind human cd137 and uses thereof

Country Status (17)

CountryLink
US (9)US10716851B2 (en)
EP (1)EP3652209A2 (en)
JP (3)JP7402521B2 (en)
KR (2)KR20240147708A (en)
CN (2)CN111278858B (en)
AU (1)AU2018301393B2 (en)
BR (1)BR112020000719A2 (en)
CA (1)CA3069438A1 (en)
CO (1)CO2020000214A2 (en)
IL (1)IL271696A (en)
MA (1)MA49565A (en)
MX (1)MX2020000342A (en)
MY (1)MY202336A (en)
PE (1)PE20200757A1 (en)
SG (3)SG11201913137VA (en)
TW (1)TWI820031B (en)
WO (1)WO2019014328A2 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
TWI820031B (en)2017-07-112023-11-01美商坎伯斯治療有限責任公司Agonist antibodies that bind human cd137 and uses thereof
WO2019036855A1 (en)2017-08-212019-02-28Adagene Inc.Anti-cd137 molecules and use thereof
WO2019089753A2 (en)2017-10-312019-05-09Compass Therapeutics LlcCd137 antibodies and pd-1 antagonists and uses thereof
WO2019100052A2 (en)*2017-11-202019-05-23Compass Therapeutics LlcCd137 antibodies and tumor antigen-targeting antibodies and uses thereof
WO2019148445A1 (en)2018-02-022019-08-08Adagene Inc.Precision/context-dependent activatable antibodies, and methods of making and using the same
AU2020208397A1 (en)*2019-01-162021-08-12Compass Therapeutics LlcFormulations of antibodies that bind human CD137 and uses thereof
US20200407440A1 (en)2019-04-242020-12-31Magenta Therapeutics, Inc.Amatoxin antibody-drug conjugates and uses thereof
WO2021016451A1 (en)*2019-07-242021-01-28Agonox, Inc.Cd63 agonist-related methods and compositions
TW202144395A (en)*2020-02-122021-12-01日商中外製藥股份有限公司Anti-CD137 antigen-binding molecule for use in cancer treatment
US20230106973A1 (en)2020-02-172023-04-06Board Of Regents, The University Of Texas SystemMethods for expansion of tumor infiltrating lymphocytes and use thereof
WO2021226883A1 (en)*2020-05-132021-11-18Adagene AgCompositions and methods for treating cancer submission of sequence listing on ascii text file
CN116249555A (en)2020-05-192023-06-09勃林格殷格翰国际有限公司Binding molecules for cancer treatment
CN113842456B (en)*2020-06-282022-07-26上海齐鲁制药研究中心有限公司Anti-human 4-1BB monoclonal antibody preparation and application thereof
WO2024040195A1 (en)2022-08-172024-02-22Capstan Therapeutics, Inc.Conditioning for in vivo immune cell engineering
WO2024109678A1 (en)*2022-11-212024-05-30Beigene, Ltd.Anti-cd137 antibodies and methods of use
WO2024249954A1 (en)2023-05-312024-12-05Capstan Therapeutics, Inc.Lipid nanoparticle formulations and compositions
WO2024249362A1 (en)*2023-06-012024-12-05The Regents Of The University Of CaliforniaRare antibody phage isolation and discrimination (rapid) biological panning
US20250127728A1 (en)2023-10-052025-04-24Capstan Therapeutics, Inc.Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025076113A1 (en)2023-10-052025-04-10Capstan Therapeutics, Inc.Ionizable cationic lipids with conserved spacing and lipid nanoparticles

Family Cites Families (250)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US3773919A (en)1969-10-231973-11-20Du PontPolylactide-drug mixtures
US3710795A (en)1970-09-291973-01-16Alza CorpDrug-delivery device with stretched, rate-controlling membrane
US4263428A (en)1978-03-241981-04-21The Regents Of The University Of CaliforniaBis-anthracycline nucleic acid function inhibitors and improved method for administering the same
IE52535B1 (en)1981-02-161987-12-09Ici PlcContinuous release pharmaceutical compositions
US4433059A (en)1981-09-081984-02-21Ortho Diagnostic Systems Inc.Double antibody conjugate
US4444878A (en)1981-12-211984-04-24Boston Biomedical Research Institute, Inc.Bispecific antibody determinants
DE3374837D1 (en)1982-02-171988-01-21Ciba Geigy AgLipids in the aqueous phase
NZ207394A (en)1983-03-081987-03-06Commw Serum Lab CommissionDetecting or determining sequence of amino acids
US4496654A (en)1983-04-081985-01-29QuidelDetection of HCG with solid phase support having avidin coating
HUT35524A (en)1983-08-021985-07-29Hoechst AgProcess for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
DE3474511D1 (en)1983-11-011988-11-17Terumo CorpPharmaceutical composition containing urokinase
EP0173552B1 (en)1984-08-241991-10-09The Upjohn CompanyRecombinant dna compounds and the expression of polypeptides such as tpa
US5168062A (en)1985-01-301992-12-01University Of Iowa Research FoundationTransfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4676980A (en)1985-09-231987-06-30The United States Of America As Represented By The Secretary Of The Department Of Health And Human ServicesTarget specific cross-linked heteroantibodies
US6548640B1 (en)1986-03-272003-04-15Btg International LimitedAltered antibodies
US5869620A (en)1986-09-021999-02-09Enzon, Inc.Multivalent antigen-binding proteins
US4863457A (en)1986-11-241989-09-05Lee David ADrug delivery device
US5026773A (en)1987-03-111991-06-25Samuel SteelApparatus for a solid phase synthesis of peptide analogs
DE3883899T3 (en)1987-03-181999-04-22Sb2, Inc., Danville, Calif. CHANGED ANTIBODIES.
JPH021556A (en)1988-06-091990-01-05Snow Brand Milk Prod Co LtdHybrid antibody and production thereof
US5223409A (en)1988-09-021993-06-29Protein Engineering Corp.Directed evolution of novel binding proteins
WO1990002809A1 (en)1988-09-021990-03-22Protein Engineering CorporationGeneration and selection of recombinant varied binding proteins
US6303121B1 (en)1992-07-302001-10-16Advanced Research And TechnologyMethod of using human receptor protein 4-1BB
US6362325B1 (en)1988-11-072002-03-26Advanced Research And Technology Institute, Inc.Murine 4-1BB gene
EP0368684B2 (en)1988-11-112004-09-29Medical Research CouncilCloning immunoglobulin variable domain sequences.
US5530101A (en)1988-12-281996-06-25Protein Design Labs, Inc.Humanized immunoglobulins
US6291159B1 (en)1989-05-162001-09-18Scripps Research InstituteMethod for producing polymers having a preselected activity
US6291158B1 (en)1989-05-162001-09-18Scripps Research InstituteMethod for tapping the immunological repertoire
DE3920358A1 (en)1989-06-221991-01-17Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
US5071909A (en)1989-07-261991-12-10Millipore CorporationImmobilization of proteins and peptides on insoluble supports
US5164188A (en)1989-11-221992-11-17Visionex, Inc.Biodegradable ocular implants
US5859205A (en)1989-12-211999-01-12Celltech LimitedHumanised antibodies
US5780225A (en)1990-01-121998-07-14StratageneMethod for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
AU7247191A (en)1990-01-111991-08-05Molecular Affinities CorporationProduction of antibodies using gene libraries
ES2336444T3 (en)1990-02-012010-04-13Siemens Healthcare Diagnostics Products Gmbh OBTAINING AND USE OF HUMAN ANTIBODY GYNOTECES ("HUMAN ANTIBODY BANKS").
CZ280777B6 (en)1990-02-021996-04-17Ústav Organické Chemie A Biochemie AvčrProcess of multistep synthesis of peptides on planar carriers and apparatus for making the same
US5273743A (en)1990-03-091993-12-28Hybritech IncorporatedTrifunctional antibody-like compounds as a combined diagnostic and therapeutic agent
US5427908A (en)1990-05-011995-06-27Affymax Technologies N.V.Recombinant library screening methods
GB9012995D0 (en)1990-06-111990-08-01Celltech LtdMultivalent antigen-binding proteins
US6172197B1 (en)1991-07-102001-01-09Medical Research CouncilMethods for producing members of specific binding pairs
GB9015198D0 (en)1990-07-101990-08-29Brien Caroline J OBinding substance
US5698426A (en)1990-09-281997-12-16Ixsys, IncorporatedSurface expression libraries of heteromeric receptors
KR0185215B1 (en)1990-11-301999-05-01요시다 쇼오지 Sustained release eye drops
CA2405246A1 (en)1990-12-031992-06-11Genentech, Inc.Enrichment method for variant proteins with alterred binding properties
US5582996A (en)1990-12-041996-12-10The Wistar Institute Of Anatomy & BiologyBifunctional antibodies and method of preparing same
DE69233750D1 (en)1991-04-102009-01-02Scripps Research Inst Libraries of heterodimeric receptors using phagemids
DE4118120A1 (en)1991-06-031992-12-10Behringwerke Ag TETRAVALENT BISPECIFIC RECEPTORS, THEIR PRODUCTION AND USE
US6511663B1 (en)1991-06-112003-01-28Celltech R&D LimitedTri- and tetra-valent monospecific antigen-binding proteins
US5637481A (en)1993-02-011997-06-10Bristol-Myers Squibb CompanyExpression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell
NL9101953A (en)1991-11-211993-06-16Seed Capital Investments TESTING DEVICE CONTAINING A PLATE WITH A MULTIPLE OF WELLS WITH AN ASSOCIATED DOSING DEVICE, AND A KIT INCLUDING THESE DEVICES AND USE OF THE DEVICES.
US5932448A (en)1991-11-291999-08-03Protein Design Labs., Inc.Bispecific antibody heterodimers
ATE463573T1 (en)1991-12-022010-04-15Medimmune Ltd PRODUCTION OF AUTOANTIBODIES ON PHAGE SURFACES BASED ON ANTIBODIES SEGMENT LIBRARIES
ATE295420T1 (en)1992-02-062005-05-15Chiron Corp MARKER FOR CANCER AND BIOSYNTHETIC BINDING PROTEIN FOR IT
US5714350A (en)1992-03-091998-02-03Protein Design Labs, Inc.Increasing antibody affinity by altering glycosylation in the immunoglobulin variable region
US5733743A (en)1992-03-241998-03-31Cambridge Antibody Technology LimitedMethods for producing members of specific binding pairs
ATE165113T1 (en)1992-05-081998-05-15Creative Biomolecules Inc MULTI-VALUE CHIMERIC PROTEINS ANALOGUE AND METHOD FOR THE APPLICATION THEREOF
US5287082A (en)1992-07-021994-02-15Cornell Research Foundation, Inc.Submicron isolated, released resistor structure
US6005079A (en)1992-08-211999-12-21Vrije Universiteit BrusselsImmunoglobulins devoid of light chains
DE69334305D1 (en)1992-08-212010-01-28Univ Bruxelles Immunoglobulins without light chains
EP1550729B1 (en)1992-09-252009-05-27Avipep Pty LimitedTarget binding polypeptide comprising an IG-like VL domain linked to an IG-like VH domain
GB9221657D0 (en)1992-10-151992-11-25Scotgen LtdRecombinant bispecific antibodies
US5837821A (en)1992-11-041998-11-17City Of HopeAntibody construct
GB9323648D0 (en)1992-11-231994-01-05Zeneca LtdProteins
ES2156149T3 (en)1992-12-042001-06-16Medical Res Council MULTIVALENT AND MULTI-SPECIFIC UNION PROTEINS, ITS MANUFACTURE AND USE.
ES2162863T3 (en)1993-04-292002-01-16Unilever Nv PRODUCTION OF ANTIBODIES OR FRAGMENTS (FUNCTIONALIZED) OF THE SAME DERIVED FROM HEAVY CHAIN IMMUNOGLOBULINS OF CAMELIDAE.
US7138500B1 (en)1993-05-072006-11-21Immunex CorporationAntibodies to human 4-1BB
US7211259B1 (en)1993-05-072007-05-01Immunex Corporation4-1BB polypeptides and DNA encoding 4-1BB polypeptides
CA2163345A1 (en)1993-06-161994-12-22Susan Adrienne MorganAntibodies
US6476198B1 (en)1993-07-132002-11-05The Scripps Research InstituteMultispecific and multivalent antigen-binding polypeptide molecules
US5635602A (en)1993-08-131997-06-03The Regents Of The University Of CaliforniaDesign and synthesis of bispecific DNA-antibody conjugates
WO1995007984A1 (en)1993-09-161995-03-23Indiana University FoundationHuman receptor h4-1bb
CA2108401A1 (en)1993-09-271995-03-28Martin LotzReceptor induced by lymphocyte activation in imflammatory response
WO1995009917A1 (en)1993-10-071995-04-13The Regents Of The University Of CaliforniaGenetically engineered bispecific tetravalent antibodies
EP0733070A1 (en)1993-12-081996-09-25Genzyme CorporationProcess for generating specific antibodies
ATE300610T1 (en)1994-01-312005-08-15Univ Boston LIBRARIES OF POLYCLONAL ANTIBODIES
US5516637A (en)1994-06-101996-05-14Dade International Inc.Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
JP3659261B2 (en)1994-10-202005-06-15モルフォシス・アクチェンゲゼルシャフト Targeted heterojunction of a recombinant protein to a multifunctional complex
US5556752A (en)1994-10-241996-09-17Affymetrix, Inc.Surface-bound, unimolecular, double-stranded DNA
US5731168A (en)1995-03-011998-03-24Genentech, Inc.Method for making heteromultimeric polypeptides
JP2911056B2 (en)1995-04-081999-06-23株式会社エルジ化学 Monoclonal antibody specific for human 4-1BB and cell line producing the same
DE69633175T2 (en)1995-05-232005-08-11Morphosys Ag MULTIMETER PROTEINS
EP0859841B1 (en)1995-08-182002-06-19MorphoSys AGProtein/(poly)peptide libraries
US5989830A (en)1995-10-161999-11-23Unilever Patent Holdings BvBifunctional or bivalent antibody fragment analogue
JP2978435B2 (en)1996-01-241999-11-15チッソ株式会社 Method for producing acryloxypropyl silane
US5874240A (en)1996-03-151999-02-23Human Genome Sciences, Inc.Human 4-1BB receptor splicing variant
ES2225961T3 (en)1996-04-042005-03-16Unilever N.V. MULTIVALLY AND MULTI SPECIFIC ANTIGEN UNION PROTEIN.
AU3117697A (en)1996-05-061997-11-26Uab Research Foundation, TheRadiolabeled fusion toxins for cancer therapy
WO1998016249A1 (en)1996-10-111998-04-23Bristol-Myers Squibb CompanyMethods and compositions for immunomodulation
US6544523B1 (en)1996-11-132003-04-08Chiron CorporationMutant forms of Fas ligand and uses thereof
AU7266898A (en)1997-04-301998-11-24Enzon, Inc.Single-chain antigen-binding proteins capable of glycosylation, production and uses thereof
US20020062010A1 (en)1997-05-022002-05-23Genentech, Inc.Method for making multispecific antibodies having heteromultimeric and common components
US20030207346A1 (en)1997-05-022003-11-06William R. ArathoonMethod for making multispecific antibodies having heteromultimeric and common components
EP1012280B1 (en)1997-06-112004-11-10Borean Pharma A/STrimerising module
EP1027439B1 (en)1997-10-272010-03-17Bac Ip B.V.Multivalent antigen-binding proteins
ES2234241T3 (en)1998-01-232005-06-16Vlaams Interuniversitair Instituut Voor Biotechnologie DERIVATIVES OF ANTIBODY OF MULTIPLE PURPOSES.
DE69937291T2 (en)1998-04-022008-07-10Genentech, Inc., South San Francisco ANTIBODY VARIANTS AND FRAGMENTS THEREOF
US6194551B1 (en)1998-04-022001-02-27Genentech, Inc.Polypeptide variants
CZ121599A3 (en)1998-04-091999-10-13Aventis Pharma Deutschland GmbhSingle-chain molecule binding several antigens, process of its preparation and medicament in which the molecule is comprised
DE19819846B4 (en)1998-05-052016-11-24Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalent antibody constructs
GB9812545D0 (en)1998-06-101998-08-05Celltech Therapeutics LtdBiological products
US6333396B1 (en)1998-10-202001-12-25Enzon, Inc.Method for targeted delivery of nucleic acids
US6995259B1 (en)1998-10-232006-02-07Sirna Therapeutics, Inc.Method for the chemical synthesis of oligonucleotides
US6818749B1 (en)*1998-10-312004-11-16The United States Of America As Represented By The Department Of Health And Human ServicesVariants of humanized anti carcinoma monoclonal antibody cc49
EP1176195B1 (en)1999-04-092013-05-22Kyowa Hakko Kirin Co., Ltd.Method for controlling the activity of immunologically functional molecule
US7527787B2 (en)2005-10-192009-05-05Ibc Pharmaceuticals, Inc.Multivalent immunoglobulin-based bioactive assemblies
US7534866B2 (en)2005-10-192009-05-19Ibc Pharmaceuticals, Inc.Methods and compositions for generating bioactive assemblies of increased complexity and uses
US20030118588A1 (en)1999-05-222003-06-26Linda DiehlInduction of anti-tumor CTL immunity through in vivo triggering of 4-1BB and/or CD40
EA004635B1 (en)1999-08-172004-06-24Байоджен, Инк.Baff receptor (bcma), an immunoregulatory agent
CN101289511A (en)2000-04-112008-10-22杰南技术公司Multivalent antibodies and uses therefore
US8288322B2 (en)2000-04-172012-10-16Dyax Corp.Methods of constructing libraries comprising displayed and/or expressed members of a diverse family of peptides, polypeptides or proteins and the novel libraries
JP2004511430A (en)2000-05-242004-04-15イムクローン システムズ インコーポレイティド Bispecific immunoglobulin-like antigen binding protein and production method
EP1294904A1 (en)2000-06-302003-03-26Vlaams Interuniversitair Instituut voor Biotechnologie vzw.Heterodimeric fusion proteins
CN1461344A (en)2000-07-252003-12-10免疫医疗公司Multivalent target binding protein
US6946292B2 (en)2000-10-062005-09-20Kyowa Hakko Kogyo Co., Ltd.Cells producing antibody compositions with increased antibody dependent cytotoxic activity
EP1197755A1 (en)2000-10-112002-04-17Pepscan Systems B.V.Identification of protein binding sites
KR100870123B1 (en)2000-10-202008-11-25츄가이 세이야꾸 가부시키가이샤 Low Molecularized Agonist Antibodies
CA2432377C (en)2000-12-182012-10-09Dyax Corp.Focused libraries of genetic packages
US7829084B2 (en)2001-01-172010-11-09Trubion Pharmaceuticals, Inc.Binding constructs and methods for use thereof
AU2002247826A1 (en)2001-03-132002-09-24University College LondonSpecific binding members
DE60237282D1 (en)2001-06-282010-09-23Domantis Ltd DOUBLE-SPECIFIC LIGAND AND ITS USE
US6833441B2 (en)2001-08-012004-12-21Abmaxis, Inc.Compositions and methods for generating chimeric heteromultimers
ATE346866T1 (en)2001-09-142006-12-15Affimed Therapeutics Ag MULTIMERIC, SINGLE CHAIN, TANDEM FV ANTIBODIES
DE60232895D1 (en)2001-10-092009-08-20Mayo Foundation USE OF AGONISTIC 4-1BB ANTIBODIES TO IMPROVE THE IMMUNE RESPONSE
US20030211078A1 (en)2001-12-072003-11-13Heavner George A.Pseudo-antibody constructs
WO2003087341A2 (en)2002-01-232003-10-23The University Of Utah Research FoundationTargeted chromosomal mutagenesis using zinc finger nucleases
CA2478011C (en)2002-03-012013-05-21Immunomedics, Inc.Bispecific antibody point mutations for enhancing rate of clearance
AU2003218382B2 (en)2002-03-212007-12-13Sangamo Therapeutics, Inc.Methods and compositions for using zinc finger endonucleases to enhance homologous recombination
EP1500665B1 (en)2002-04-152011-06-15Chugai Seiyaku Kabushiki KaishaMETHODS FOR CONSTRUCTING scDb LIBRARIES
AU2003237456A1 (en)2002-06-052003-12-22Sopherion Therapeutics, Inc.Method to screen ligands using eukaryotic cell display
US20040109847A1 (en)*2002-07-152004-06-10Lieping ChenTreatment and prophylaxis with 4-1BB-binding agents
US6887673B2 (en)2002-07-302005-05-03Bristol-Myers Squibb CompanyHumanized antibodies against human 4-1BB
CA2497913C (en)2002-09-052014-06-03California Institute Of TechnologyUse of chimeric nucleases to stimulate gene targeting
AU2003290059A1 (en)2002-12-162004-07-09Herbert SchwarzUse of cd137 antagonists for the treatment of tumors
GB0230203D0 (en)2002-12-272003-02-05Domantis LtdFc fusion
AU2003300184B8 (en)2002-12-302009-12-033M Innovative Properties CompanyImmunostimulatory combinations
GB0305702D0 (en)2003-03-122003-04-16Univ BirminghamBispecific antibodies
CA2522819A1 (en)2003-04-222004-11-04Immunomedics, Inc.Polyvalent protein complex
NZ544924A (en)2003-06-272009-03-31Biogen Idec IncModified binding molecules comprising connecting peptides
WO2005004809A2 (en)2003-07-012005-01-20Immunomedics, Inc.Multivalent carriers of bi-specific antibodies
US7696322B2 (en)2003-07-282010-04-13Catalent Pharma Solutions, Inc.Fusion antibodies
US7888121B2 (en)2003-08-082011-02-15Sangamo Biosciences, Inc.Methods and compositions for targeted cleavage and recombination
US8409861B2 (en)2003-08-082013-04-02Sangamo Biosciences, Inc.Targeted deletion of cellular DNA sequences
EP1688439A4 (en)2003-10-082007-12-19Kyowa Hakko Kogyo KkFused protein composition
AR046094A1 (en)*2003-10-102005-11-23Bristol Myers Squibb Co COMPLETELY HUMAN ANTIBODIES AGAINST HUMAN 4-1BB
US7288638B2 (en)*2003-10-102007-10-30Bristol-Myers Squibb CompanyFully human antibodies against human 4-1BB
US7435596B2 (en)2004-11-042008-10-14St. Jude Children's Research Hospital, Inc.Modified cell line and method for expansion of NK cell
WO2005062916A2 (en)2003-12-222005-07-14Centocor, Inc.Methods for generating multimeric molecules
GB0329825D0 (en)2003-12-232004-01-28Celltech R&D LtdBiological products
US20050266425A1 (en)2003-12-312005-12-01Vaccinex, Inc.Methods for producing and identifying multispecific antibodies
WO2005073384A2 (en)2004-01-282005-08-11Research Development FoundationHuman soluble neuropilin-1 primary polyadenylation signal and uses thereof
US8383575B2 (en)2004-01-302013-02-26Paul Scherrer Institut(DI)barnase-barstar complexes
US8685435B2 (en)2004-04-302014-04-01Allergan, Inc.Extended release biodegradable ocular implants
DK1751181T3 (en)2004-06-022012-11-26Adalta Pty Ltd BINDING PARTS BASED ON HAJ IgNAR DOMAINS
EP1786918A4 (en)2004-07-172009-02-11Imclone Systems IncNovel tetravalent bispecific antibody
US20060040354A1 (en)2004-07-202006-02-23O'keefe Theresa LNovel polyadenylation signal for use in expression vectors
MX2007002856A (en)2004-09-022007-09-25Genentech IncHeteromultimeric molecules.
WO2006029220A2 (en)2004-09-082006-03-16Ohio State University Research FoundationCombination therapy with anti-ctla4 and anti-4-1bb antibodies
JP4942664B2 (en)2005-02-012012-05-30モーフォシス アーゲー Libraries and methods for isolating antibodies
US20080019905A9 (en)2005-02-182008-01-24Strome Scott EMethod of using an anti-CD137 antibody as an agent for radioimmunotherapy or radioimmunodetection
DK3050963T3 (en)2005-03-312019-12-09Chugai Pharmaceutical Co Ltd Process for producing polypeptide by arrangement control
AU2006232920B2 (en)2005-04-062011-09-29Ibc Pharmaceuticals, Inc.Methods for generating stably linked complexes composed of homodimers, homotetramers or dimers of dimers and uses
CA2605024C (en)2005-04-152018-05-22Macrogenics, Inc.Covalent diabodies and uses thereof
US20060263367A1 (en)2005-05-232006-11-23Fey Georg HBispecific antibody devoid of Fc region and method of treatment using same
KR100694508B1 (en)2005-05-242007-03-13울산대학교 산학협력단 Pharmaceutical composition for the treatment of cancer diseases comprising H4 antibody and immunotherapy method of cancer using the same
CA2615532C (en)2005-07-262016-06-28Sangamo Biosciences, Inc.Targeted integration and expression of exogenous nucleic acid sequences
US7612181B2 (en)2005-08-192009-11-03Abbott LaboratoriesDual variable domain immunoglobulin and uses thereof
NZ597168A (en)2005-08-192013-07-26Abbott LabDual variable domain immunoglobin and uses thereof
EP1757622B1 (en)2005-08-262009-12-23PLS Design GmbHBivalent IgY antibody constructs for diagnostic and therapeutic applications
WO2007044887A2 (en)2005-10-112007-04-19Transtarget, Inc.Method for producing a population of homogenous tetravalent bispecific antibodies
US7790655B2 (en)2005-10-142010-09-07Medimmune, LlcCell display of antibody libraries
EP1957531B1 (en)2005-11-072016-04-13Genentech, Inc.Binding polypeptides with diversified and consensus vh/vl hypervariable sequences
EP1962961B1 (en)2005-11-292013-01-09The University Of SydneyDemibodies: dimerisation-activated therapeutic agents
US20090196877A1 (en)2005-12-022009-08-06The Johns Hopkins UniversityNovel Method to Increase Memory T Lymphocytes and Enhance Their Functions
EP1986684A2 (en)2006-02-152008-11-05ImClone Systems IncorporatedFunctional antibodies
CN103073639A (en)2006-03-172013-05-01比奥根艾迪克Ma公司Stabilized polypeptide compositions
WO2007108152A1 (en)2006-03-232007-09-27Tohoku UniversityHigh functional bispecific antibody
PL1999154T3 (en)2006-03-242013-03-29Merck Patent GmbhEngineered heterodimeric protein domains
US8946391B2 (en)2006-03-242015-02-03The Regents Of The University Of CaliforniaConstruction of a multivalent scFv through alkyne-azide 1,3-dipolar cycloaddition
EP2009101B1 (en)2006-03-312017-10-25Chugai Seiyaku Kabushiki KaishaAntibody modification method for purifying bispecific antibody
US8501185B2 (en)2006-05-252013-08-06Bayer Healthcare LlcDimeric molecular complexes
US20070274985A1 (en)2006-05-262007-11-29Stefan DubelAntibody
NZ573646A (en)2006-06-122012-04-27Wyeth LlcSingle-chain multivalent binding proteins with effector function
KR100745488B1 (en)2006-07-042007-08-02학교법인 울산공업학원 Pharmaceutical composition for the prevention and treatment of cancer diseases, including anti-4-1BB antibody and chemical anticancer agent
JP5959795B2 (en)2006-08-182016-08-02アーメイゲン・テクノロジーズ・インコーポレイテッドArmagen Technologies, Inc. Substances for blood-brain barrier delivery
WO2008027236A2 (en)2006-08-302008-03-06Genentech, Inc.Multispecific antibodies
US20080241139A1 (en)2006-10-312008-10-02Regents Of The University Of ColoradoAdjuvant combinations comprising a microbial tlr agonist, a cd40 or 4-1bb agonist, and optionally an antigen and the use thereof for inducing a synergistic enhancement in cellular immunity
EP2078040B1 (en)2006-11-022017-06-28Daniel J. CaponMethods of producing hybrid polypeptides with moving parts
CA2681974C (en)2007-03-292019-12-31Genmab A/SBispecific antibodies and methods for production thereof
WO2008131242A1 (en)2007-04-182008-10-30Zymogenetics, Inc.Single chain fc, methods of making and methods of treatment
US20090155275A1 (en)2007-07-312009-06-18Medimmune, LlcMultispecific epitope binding proteins and uses thereof
ES2628395T3 (en)2007-08-152017-08-02Bayer Pharma Aktiengesellschaft Protease Regulated Antibody
US8877688B2 (en)2007-09-142014-11-04Adimab, LlcRationally designed, synthetic antibody libraries and uses therefor
BRPI0816785A2 (en)2007-09-142017-05-02Adimab Inc rationally designed synthetic antibody libraries, and uses thereof
US7947495B2 (en)2007-11-012011-05-24Abbott Biotherapeutics Corp.Immunoglobulin display vectors
MX2010005783A (en)2007-11-272010-08-10Ablynx NvAmino acid sequences directed against heterodimeric cytokines and/or their receptors and polypeptides comprising the same.
CN101932608A (en)2007-11-302010-12-29葛兰素集团有限公司Antigen-binding constructs
US8242247B2 (en)2007-12-212012-08-14Hoffmann-La Roche Inc.Bivalent, bispecific antibodies
US9266967B2 (en)2007-12-212016-02-23Hoffmann-La Roche, Inc.Bivalent, bispecific antibodies
US8227577B2 (en)2007-12-212012-07-24Hoffman-La Roche Inc.Bivalent, bispecific antibodies
US20090162359A1 (en)2007-12-212009-06-25Christian KleinBivalent, bispecific antibodies
EP3061770B8 (en)2008-01-072020-02-12Amgen Inc.Method for making antibody fc-heterodimeric molecules using electrostatic steering effects
EP2238165B1 (en)2008-01-072017-07-05Government of the United States of America, as represented by the Secretary, Department of Health and Human ServicesAnti-hiv domain antibodies and method of making and using same
DE102008010362A1 (en)2008-02-182009-08-20Florian Prof. Dr. Lang Sgk1 as a therapeutic and diagnostic target for viral diseases
ES2528963T3 (en)2008-04-242015-02-13Dyax Corp. Genetic package libraries comprising new designs of CDR1, CDR2, and CDR3 of HC and new designs of CDR1, CDR2, and CDR3 of LC
CA2736277C (en)2008-09-102016-06-21Philochem AgDisplay library for antibody selection
WO2010042433A1 (en)2008-10-062010-04-15Bristol-Myers Squibb CompanyCombination of cd137 antibody and ctla-4 antibody for the treatment of proliferative diseases
WO2010129304A2 (en)2009-04-272010-11-11Oncomed Pharmaceuticals, Inc.Method for making heteromultimeric molecules
US20120076722A1 (en)2009-05-142012-03-29University Of Maryland, BaltimoreMethods for treating cancers and diseases associated with 4-1bb (cd137) expression
MX392642B (en)2009-07-172025-03-19Bioatla Llc SIMULTANEOUS INTEGRATED SELECTION AND DEVELOPMENT OF PROTEIN/ANTIBODY PERFORMANCE AND EXPRESSION IN PRODUCTION HOSTS.
SG10201408401RA (en)2009-09-162015-01-29Genentech IncCoiled coil and/or tether containing protein complexes and uses thereof
CA2781311C (en)2009-12-072019-03-12The Board Of Trustees Of The Leland Stanford Junior UniversityMethods for enhancing anti-tumor antibody therapy
MX391041B (en)2010-04-202025-03-04Genmab As PROTEINS CONTAINING FC OF HETERODIMERIC ANTIBODIES AND METHODS FOR PRODUCTION THEREOF.
JP6266343B2 (en)2010-07-162018-01-24アディマブ, エルエルシー Antibody library
CN105481983B (en)*2010-09-092021-09-03辉瑞公司4-1BB binding molecules
TR201905909T4 (en)2011-04-192019-05-21Pfizer Combinations of anti-4-1bb antibodies and adcc inducing antibodies for cancer therapy.
CN102760801B (en)2011-04-292015-04-01清华大学Preparation method of light-emitting diode
CN118290588A (en)2011-10-272024-07-05健玛保 Heterodimer protein generation
US9401875B2 (en)2012-06-012016-07-26Nippon Telegraph And Telephone CorporationPacket transfer processing method and packet transfer processing device
JP6403166B2 (en)2012-08-032018-10-10ダナ−ファーバー キャンサー インスティテュート, インコーポレイテッド Single antigen anti-PD-L1 and PD-L2 double-binding antibodies and methods of use thereof
US8697359B1 (en)2012-12-122014-04-15The Broad Institute, Inc.CRISPR-Cas systems and methods for altering expression of gene products
WO2014134165A1 (en)2013-02-262014-09-04Memorial Sloan-Kettering Cancer CenterCompositions and methods for immunotherapy
EP3066127A1 (en)2013-11-062016-09-14Bristol-Myers Squibb CompanyImmunotherapeutic dosing regimens and combinations thereof
WO2015103072A1 (en)2013-12-302015-07-09Epimab BiotherapeuticsFabs-in-tandem immunoglobulin and uses thereof
US10927154B2 (en)2014-01-132021-02-23Pieris Pharmaceuticals GmbhMulti-specific polypeptide useful for localized tumor immunomodulation
EP3686219A1 (en)2014-02-042020-07-29Pfizer IncCombination of a pd-1 antagonist and a 4-1bb agonist for treating cancer
US9300829B2 (en)2014-04-042016-03-29Canon Kabushiki KaishaImage reading apparatus and correction method thereof
UA119352C2 (en)*2014-05-012019-06-10Тева Фармасьютикалз Острейліа Пті Лтд COMBINATION OF LENALIDOMIDE OR POMALIDOMIDE AND STRUCTURES OF ANTI-CD38 ANTIBODY-ATHENED INTERPHERONE ALPHA-2B AND METHOD OF TREATMENT38
AU2015264528A1 (en)2014-05-212016-11-03Kyowa Hakko Kirin Co., Ltd.Combination of an anti-CCR4 antibody and a 4-1BB agonist for treating cancer
WO2015188047A1 (en)2014-06-062015-12-10University Of Maryland, BaltimoreANTI-CD-137 MONOCLONAL ANTIBODIES WITH DISTINCT FcγR BINDING ABILITIES FOR TREATMENT OF CANCER OR AUTOIMMUNITY
EP3183269A2 (en)2014-08-222017-06-28Bristol-Myers Squibb CompanyTreatment of cancer using a combination of an anti-pd-1 antibody and an anti-cd137 antibody
WO2016115274A1 (en)2015-01-142016-07-21Compass Therapeutics LlcMultispecific immunomodulatory antigen-binding constructs
MX2017010793A (en)2015-02-222018-07-06Sorrento Therapeutics IncAntibody therapeutics that bind cd137.
KR20250004095A (en)2015-04-172025-01-07브리스톨-마이어스 스큅 컴퍼니Compositions comprising a combination of an anti-pd-1 antibody and another antibody
CN107636014B (en)2015-05-042021-12-07皮里斯制药有限公司Anti-cancer fusion polypeptides
US11008396B2 (en)2015-05-212021-05-18Alligator Bioscience AbPolypeptides
WO2017004079A1 (en)*2015-06-292017-01-05Biomed Valley Discoveries, Inc.Lpt-723 and immune checkpoint inhibitor combinations and methods of treatment
US20180214550A1 (en)2015-07-072018-08-02INSERM (Institut National de la Santé et de la Recherche Médicale)Methods and pharmaceutical compositions for enhancing nk cell killing activities
US20180251548A1 (en)2015-09-142018-09-06Compass Therapeutics LlcCompositions and methods for treating cancer via antagonism of the cd155/tigit pathway and tgf-beta
RU2018116402A (en)*2015-10-072019-11-07Ф. Хоффманн-Ля Рош Аг BESPECIFIC ANTIBODIES FOUR PRINCIPLES REGARDING THE COSTIMULATORY TNF RECEPTOR
EP3402519A4 (en)2016-01-132020-01-08Compass Therapeutics LLCMultispecific immunomodulatory antigen-binding constructs
AU2017211540B2 (en)2016-01-252020-04-30Pfizer Inc.Combination of an OX40 agonist and a 4-1BB agonist monoclonal antibody for treating cancer
CN118185874A (en)2016-04-042024-06-14苏黎世联邦理工学院Recombinant mammalian B cell
WO2017181034A1 (en)2016-04-142017-10-19Bristol-Myers Squibb CompanyCombination therapy using an anti-fucosyl-gm1 antibody and an anti-cd137 antibody
WO2017205745A1 (en)2016-05-272017-11-30Abbvie Biotherapeutics Inc.Anti-4-1bb antibodies and their uses
CN112210010B (en)2017-01-062023-12-05优特力克斯有限公司 Anti-human 4-1BB antibodies and their applications
CN110546166B (en)2017-04-132024-03-29艾吉纳斯公司anti-CD 137 antibodies and methods of use thereof
TWI820031B (en)2017-07-112023-11-01美商坎伯斯治療有限責任公司Agonist antibodies that bind human cd137 and uses thereof
UA128388C2 (en)2017-08-012024-07-03Елі Ліллі Енд КомпаніAnti-cd137 antibodies
WO2019036855A1 (en)2017-08-212019-02-28Adagene Inc.Anti-cd137 molecules and use thereof
WO2020006605A1 (en)2018-07-042020-01-09Honeycomb Media Pty LtdMethod and system for providing incentives to users

Also Published As

Publication numberPublication date
KR20240147708A (en)2024-10-08
TW201920265A (en)2019-06-01
CO2020000214A2 (en)2020-04-24
IL271696A (en)2020-02-27
US11752207B2 (en)2023-09-12
EP3652209A2 (en)2020-05-20
US10279040B1 (en)2019-05-07
US10716851B2 (en)2020-07-21
MX2020000342A (en)2020-08-17
JP2020526211A (en)2020-08-31
TWI820031B (en)2023-11-01
NZ760841A (en)2024-02-23
CN111278858A (en)2020-06-12
AU2018301393B2 (en)2025-02-27
US20190224315A1 (en)2019-07-25
JP7587858B2 (en)2024-11-21
MY202336A (en)2024-04-24
US20190269776A1 (en)2019-09-05
US20200046833A1 (en)2020-02-13
US20240181050A1 (en)2024-06-06
CN118812712A (en)2024-10-22
SG10201913144TA (en)2020-03-30
CA3069438A1 (en)2019-01-17
US10434175B2 (en)2019-10-08
MA49565A (en)2020-05-20
US10350292B1 (en)2019-07-16
KR102714165B1 (en)2024-10-10
AU2018301393A1 (en)2020-02-06
US20190125866A1 (en)2019-05-02
US10279038B2 (en)2019-05-07
WO2019014328A3 (en)2019-02-21
US20200306374A1 (en)2020-10-01
US20190099488A1 (en)2019-04-04
US20190060454A1 (en)2019-02-28
KR20200035966A (en)2020-04-06
CN111278858B (en)2024-07-23
US20190015508A1 (en)2019-01-17
US10279039B2 (en)2019-05-07
JP7402521B2 (en)2023-12-21
PE20200757A1 (en)2020-07-27
JP2023015262A (en)2023-01-31
SG11201913137VA (en)2020-01-30
JP2024042106A (en)2024-03-27
WO2019014328A2 (en)2019-01-17
BR112020000719A2 (en)2020-07-14

Similar Documents

PublicationPublication DateTitle
IL271696A (en)Agonist antibodies that bind human cd137 and uses thereof
IL290842A (en)Anti-cd73 antibodies and uses thereof
ZA202102905B (en)Anti-galectin-9 antibodies and uses thereof
IL271477A (en)Anti-cd166 antibodies and uses thereof
ZA202101318B (en)Anti-phf-tau antibodies and uses thereof
IL276950A (en)Anti-cd73 antibodies and uses thereof
IL268734A (en)Anti-lag-3 antibodies and uses thereof
IL268206A (en)Bcma-targeting antibody and use thereof
IL282968A (en)Anti-nkg2a antibodies and uses thereof
IL269134A (en)Anti-par2 antibodies and uses thereof
IL273157A (en)Axl-specific antibodies and uses thereof
IL275826A (en)Anti-mct1 antibodies and uses thereof
IL281297A (en)Anti-npr1 antibodies and uses thereof
IL272476A (en)Anti-apelin antibodies and uses thereof
IL274809A (en)Anti-cxcr5 antibodies and compositions and uses thereof
IL281202A (en)Anti-tnfrsf9 antibodies and uses thereof
IL280321A (en)Anti-cxcr2 antibodies and uses thereof
ZA201906954B (en)Btla agonist antibodies and uses thereof
IL283875A (en)Anti-il-27 antibodies and uses thereof
IL277330A (en)Anti-il-27 antibodies and uses thereof
IL304781A (en)Fgf21 mimetic antibodies and uses thereof
SG11202003585VA (en)Anti-vista antibody and use thereof
IL277075A (en)Anti-phf-tau antibodies and uses thereof
IL276548A (en)Bcma-binding antibodies and uses thereof
IL275794A (en)Pac1 antibodies and uses thereof

[8]ページ先頭

©2009-2025 Movatter.jp